Skip to content
Screener

Veracyte VCYT Business Segments — Other research and development expenses

Similar metrics at other companies

Silicon Laboratories logo
SLABReportable Segment — Other research and development expenses
$56.28M+1.9%
Roivant Sciences logo
ROIVReportable Segment — Other research and development expenses
$7.86M-18.4%
Inhibrx Biosciences, Inc. logo
INBXReportable Segment — Other Research and Development Expense
$2.91M-7.8%
Archer Aviation logo
ACHRReportable Segment — Other research and development expense
$133.3M+51.1%
Crinetics Pharmaceuticals logo
CRNXReportable Segment — Other Research and Development Expense
$8.3M+23.2%
Arvinas logo
ARVNReportable Segment — Other research and development expense
$2.4M-22.6%

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$3.71B+97.6%
Enterprise value$3.48B+104%
P/E42.2×-29.1×
P/S6.9×+2.9×

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0.0×
Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.

The source filing: Veracyte’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 8:07 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001384101-26-000031
Line itemThree Months Ended March 31, 20262025
Research and development:
Compensation expense15,5479,748
Direct research and development expense4,1984,141
Other research and development expenses (4)5,4601,815
Allocation of facilities and IT expenses1,8932,016
Total research and development27,09817,720
Selling and marketing:
Compensation expense19,97217,635

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Veracyte's business segments — other research and development expenses?
Veracyte (VCYT) reported business segments — other research and development expenses of $5.46M in Q1 2026.
How has Veracyte's business segments — other research and development expenses changed year-over-year?
Veracyte's business segments — other research and development expenses increased by 200.8% year-over-year, from $1.82M to $5.46M.
What is the long-term trend for Veracyte's business segments — other research and development expenses?
Over 3 years (2022 to 2025), Veracyte's business segments — other research and development expenses has grown at a 22.1% compound annual growth rate (CAGR), from $4.67M to $8.5M.
What does business segments — other research and development expenses mean?
Includes miscellaneous research and development costs for the segment that fall outside of primary direct R&D activities. These expenses typically cover supporting infrastructure, administrative R&D overhead, or secondary innovation projects.

Ask your AI about Veracyte's business segments — other research and development expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude